180 Life Sciences Corp.
ATNF
$1.07
-$0.01-0.93%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.12M | -12.55M | -16.24M | -19.94M | -40.45M |
| Total Depreciation and Amortization | 84.20K | 103.00K | 107.60K | 105.80K | 120.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 600.40K | 7.98M | 8.65M | 8.92M | 25.19M |
| Change in Net Operating Assets | -252.50K | 224.50K | -603.90K | -14.10K | 3.45M |
| Cash from Operations | -2.69M | -4.24M | -8.09M | -10.92M | -11.69M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 969.30K | 969.30K | 969.30K | 969.30K | 1.06M |
| Total Debt Repaid | -1.28M | -1.06M | -1.05M | -1.26M | -1.17M |
| Issuance of Common Stock | 831.60K | 3.83M | 6.83M | 6.83M | 12.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -59.80K | -354.80K | -634.80K | -634.80K | -1.06M |
| Cash from Financing | 463.00K | 3.39M | 6.11M | 5.91M | 10.84M |
| Foreign Exchange rate Adjustments | -240.70K | -6.80K | 2.20K | 20.00K | -72.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.47M | -862.30K | -1.97M | -4.99M | -926.10K |
